Risk of COVID-19 for patients with cancer: A narrative overview

Baba, Mohamed Amine; Bouchriti, Youssef; Achbani, Abderrahmane; Kharbach, Ahmed; Sine, Hasnaa; Naciri, Aziz

doi:10.30935/ejmets/8257

Cited by 4 publications

(5 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As known, human MSCs have a great competence to sustain tissue homeostasis as their high potential to home into damaged tissue and their effect on a variety of biochemical and cellular processes such as immune regulation, bioenergy, and tissue regeneration [84][85][86]. These processes are attributed to direct interactions with different types of cells or by paracrine mechanisms so through the production of soluble biological factors like exosomes [87].…”

Section: Application Of Msc-derived Exosomes In Regenerative Medicinementioning

confidence: 99%

Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

et al. 2021

View full text Add to dashboard Cite

Recently, mesenchymal stem/stromal cells (MSCs) and their widespread biomedical applications have attracted great consideration from the scientific community around the world. However, reports have shown that the main populations of the transplanted MSCs are trapped in the liver, spleen, and lung upon administration, highlighting the importance of the development of cell-free therapies. Concerning rising evidence suggesting that the beneficial effects of MSC therapy are closely linked to MSC-released components, predominantly MSC-derived exosomes, the development of an MSC-based cell-free approach is of paramount importance. The exosomes are nano-sized (30–100 nm) lipid bilayer membrane vesicles, which are typically released by MSCs and are found in different body fluids. They include various bioactive molecules, such as messenger RNA (mRNA), microRNAs, proteins, and bioactive lipids, thus showing pronounced therapeutic competence for tissues recovery through the maintenance of their endogenous stem cells, the enhancement of regenerative phenotypic traits, inhibition of apoptosis concomitant with immune modulation, and stimulation of the angiogenesis. Conversely, the specific roles of MSC exosomes in the treatment of various tumors remain challenging. The development and clinical application of novel MSC-based cell-free strategies can be supported by better understanding their mechanisms, classifying the subpopulation of exosomes, enhancing the conditions of cell culture and isolation, and increasing the production of exosomes along with engineering exosomes to deliver drugs and therapeutic molecules to the target sites. In the current review, we deliver a brief overview of MSC-derived exosome biogenesis, composition, and isolation methods and discuss recent investigation regarding the therapeutic potential of MSC exosomes in regenerative medicine accompanied by their double-edged sword role in cancer.

show abstract

Section: Application Of Msc-derived Exosomes In Regenerative Medicinementioning

confidence: 99%

Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, effector NK cells secrete various cytokines and chemokines, which trigger other innate and adaptive immune cells responses. NK cell‐mediated elimination of primary acute myeloid leukemia (AML) blasts has been shown with several NK cell preparations such as in vitro‐expanded allogeneic NK cells 16‐18 . It seems that killer cell immunoglobulin‐like receptors (KIR) mismatching with their ligand (KIR‐L) largely contributes to cancer cell lysis.…”

Section: Nk Cell‐mediated Immunosurveillance Of Cancermentioning

confidence: 99%

“…NK cell-mediated elimination of primary acute myeloid leukemia (AML) blasts has been shown with several NK cell preparations such as in vitro-expanded allogeneic NK cells. [16][17][18] It seems that killer cell immunoglobulin-like receptors (KIR) mismatching with their ligand (KIR-L) largely contributes to cancer cell lysis. The elimination of AML cells by NK cells is predominantly demonstrated in monoblastic cells that express natural killer group 2 member D (NKG2D) ligands, while cells that miss the corresponding ligands are resistant to NK eradication.…”

Section: Nk Cell-med Iated Immunosurveill An Ce Of C An Cermentioning

confidence: 99%

CAR‐NK cell in cancer immunotherapy; A promising frontier

et al. 2021

View full text Add to dashboard Cite

Chimeric antigen receptors (CARs) have a unique facet of synthetic biology and offer a paradigm shift in personalized medicine as they can use and redirect the patient's immune cells to attack cancer cells. CAR‐natural killer (NK) cells combine the targeted specificity of antigens with the subsequent intracellular signaling ability of the receptors to increase their anti‐cancer functions. Importantly, CAR‐NK cells can be utilized as universal cell‐based therapy without requiring human leukocyte antigen (HLA) matching or earlier contact with tumor‐associated antigens (TAAs). Indeed, CAR‐NK cells can be adapted to recognize various antigens, hold higher proliferation capacity, and in vivo persistence, show improved infiltration into the tumors, and the ability to overcome the resistant tumor microenvironment leading to sustained cytotoxicity against tumors. Accumulating evidence from recent in vivo studies rendering CAR‐NK cell anti‐cancer competencies renewed the attention in the context of cancer immunotherapy, as these redirected effector cells can be used in the development of the “off‐the‐shelf” anti‐cancer immunotherapeutic products. In the current review, we focus on the therapeutic efficacy of CAR‐NK cell therapies for treating various human malignancies, including hematological malignancies and solid tumors, and will discuss the recent findings in this regard, with a special focus on animal studies.

show abstract

“…Oncology establishments must establish an emergency plan for postive cases [18] , a recent review recommends for cases tested postive to Covid 19, the cancer treatment must be stopped until recovery and the risk-benefit ratio of the treatment must be evaluated for those patients with glioblastoma [17].…”

Section: Radio-chemotherapy Treatmentmentioning

confidence: 99%

The Management of Glioblastomas during the SARS-CoV-19 Pandemic: A Narrative Overview

Baba

Adali

2021

EUR J BASIC MED SCI

Self Cite

View full text Add to dashboard Cite

show abstract

Risk of COVID-19 for patients with cancer: A narrative overview

Abstract: In March 2020, the WHO declared COVID-19 as a pandemic. At present, the curative vaccine has not yet been developed, older age and higher comorbidity levels are associated with more severe COVID-19 symptoms. Indeed, the cancer community currently faces many difficult questions.

Cited by 4 publications

References 11 publications

Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

CAR‐NK cell in cancer immunotherapy; A promising frontier

The Management of Glioblastomas during the SARS-CoV-19 Pandemic: A Narrative Overview

Contact Info

Product

Resources

About